Which medications are safe for treating insomnia during pregnancy?

Safe Medications for Insomnia During Pregnancy

No medications are FDA-approved for insomnia during pregnancy, and all pharmacologic agents carry some degree of uncertainty regarding fetal safety; however, when non-pharmacologic interventions fail and treatment is necessary, doxylamine (with or without pyridoxine) and diphenhydramine represent the safest first-line options based on decades of human pregnancy data, while cognitive-behavioral therapy for insomnia (CBT-I) should always be attempted first.

First-Line Non-Pharmacologic Treatment

• Cognitive-behavioral therapy for insomnia (CBT-I) must be initiated before any medication is considered during pregnancy, as it provides effective symptom relief without exposing the fetus to pharmacologic agents and maintains benefits after treatment ends. 1
• CBT-I components—including stimulus control (using the bed only for sleep, leaving the bedroom if unable to sleep within 20 minutes), sleep restriction, relaxation techniques, and cognitive restructuring—have shown preliminary efficacy in pregnant women, though high-quality randomized trials are lacking. 1
• Sleep hygiene modifications (maintaining consistent sleep-wake times, avoiding caffeine, creating a cool/dark bedroom environment, limiting evening fluids to reduce nocturia) should be implemented alongside CBT-I components. 1

Safest Pharmacologic Options When Non-Pharmacologic Treatment Fails

First-Line: Antihistamines

• Doxylamine (alone or combined with pyridoxine as Diclegis/Diclectin) is the safest first-line pharmacologic option for pregnancy-related insomnia, with extensive human pregnancy data showing no increased risk of major congenital malformations and FDA Pregnancy Category A designation for the combination product. 2, 3, 4
• Diphenhydramine is another first-line antihistamine option with decades of human pregnancy exposure data demonstrating no teratogenic risk, though it carries anticholinergic side effects (dry mouth, urinary retention, daytime sedation) that may be poorly tolerated. 3, 4
• Antihistamines should be used at the lowest effective dose for the shortest duration necessary, typically 25-50 mg of diphenhydramine or doxylamine at bedtime. 3, 4

Second-Line: Selective Agents When Antihistamines Fail

• Zolpidem has the most reassuring human pregnancy data among the Z-drugs, with multiple large cohort studies showing no increased risk of congenital malformations, preterm birth, or low birth weight when used in the first trimester, though data on continuous use throughout pregnancy remain limited. 2, 3
• Zolpidem should be prescribed at 5 mg (not 10 mg) in pregnant women due to altered pharmacokinetics and increased sensitivity during pregnancy. 2, 3
• Eszopiclone and zaleplon have insufficient human pregnancy data to recommend their use; they should be avoided unless zolpidem has failed and the clinical situation is severe. 3

Agents With Limited But Potentially Acceptable Data

• Low-dose trazodone (25-50 mg) may be considered when comorbid depression or anxiety is present, as it has been used extensively in pregnancy for depression without clear evidence of teratogenicity, though systematic data for insomnia treatment in pregnancy are lacking. 3, 4
• Melatonin 3-5 mg has theoretical appeal as a naturally occurring hormone, but human pregnancy safety data are extremely limited and it is not recommended as a first-line agent despite its widespread over-the-counter availability. 4

Medications to Avoid During Pregnancy

• Benzodiazepines (lorazepam, temazepam, clonazepam) should be avoided during pregnancy due to associations with oral clefts when used in the first trimester, neonatal withdrawal syndrome, and floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) when used near delivery. 5, 3, 4
• Ramelteon, suvorexant, lemborexant, and daridorexant have no human pregnancy data and should not be used; animal studies show potential reproductive toxicity for some orexin antagonists. 3
• Low-dose doxepin (3-6 mg) used for insomnia in non-pregnant adults is not recommended during pregnancy due to lack of safety data at hypnotic doses and concerns about neonatal withdrawal when tricyclic antidepressants are used near term. 3, 4

Treatment Algorithm for Pregnancy-Related Insomnia

Step 1: Initial Assessment (Weeks 0-2)

• Evaluate for pregnancy-related physical contributors: nocturia, gastroesophageal reflux, leg cramps, fetal movement, back pain, nasal congestion. 5, 3
• Screen for comorbid psychiatric conditions (depression, anxiety) that may require separate treatment and could be driving insomnia symptoms. 4
• Assess for primary sleep disorders (obstructive sleep apnea, restless legs syndrome) that worsen during pregnancy and require specific management. 3

Step 2: Non-Pharmacologic Intervention (Weeks 2-6)

• Initiate CBT-I with all core components (stimulus control, sleep restriction, cognitive restructuring, relaxation training). 1
• Implement pregnancy-specific sleep hygiene: left lateral sleeping position to optimize uteroplacental blood flow, pregnancy pillow for support, elevation of head of bed for reflux. 3
• Address modifiable physical symptoms: treat reflux with antacids, prescribe magnesium for leg cramps, recommend pelvic floor physical therapy for pelvic discomfort. 3

Step 3: Pharmacologic Treatment (If CBT-I Insufficient After 4-6 Weeks)

• First choice: Doxylamine 25 mg at bedtime (or doxylamine/pyridoxine combination if nausea is also present). 2, 3, 4
• Second choice: Diphenhydramine 25-50 mg at bedtime if doxylamine is ineffective or not tolerated. 3, 4
• Third choice: Zolpidem 5 mg at bedtime if antihistamines fail and insomnia is severely impacting maternal health or pregnancy outcomes. 2, 3
• Fourth choice: Low-dose trazodone 25-50 mg at bedtime when comorbid depression/anxiety is present and other agents have failed. 3, 4

Step 4: Monitoring and Reassessment (Every 2-4 Weeks)

• Reassess sleep quality, daytime functioning, and any adverse effects (morning sedation, anticholinergic symptoms). 3
• Attempt to taper medication in the second trimester when sleep often improves naturally due to decreased nocturia and stabilization of hormone levels. 5, 3
• Discontinue or minimize medication 2-4 weeks before expected delivery date to reduce risk of neonatal withdrawal or sedation. 3, 4

Critical Safety Considerations

• All sleep medications cross the placenta and enter breast milk to varying degrees; the decision to use pharmacotherapy must weigh the risks of untreated insomnia (increased risk of preterm birth, low birth weight, cesarean section, postpartum depression) against potential fetal/neonatal medication exposure. 5, 3
• Untreated severe insomnia during pregnancy is associated with adverse maternal outcomes including increased pain during labor, higher rates of operative delivery, and significantly elevated risk of postpartum depression. 5
• Pharmacokinetic changes during pregnancy (increased volume of distribution, enhanced hepatic metabolism, increased renal clearance) may require dose adjustments or more frequent dosing for some medications. 3
• Third-trimester use of any sedative-hypnotic near delivery carries risk of neonatal respiratory depression, hypotonia, and poor feeding; medications should be discontinued 1-2 weeks before expected delivery when possible. 3, 4

Common Pitfalls to Avoid

• Do not prescribe benzodiazepines for pregnancy-related insomnia despite their efficacy in non-pregnant populations, as the risks of oral clefts and neonatal complications outweigh benefits. 5, 3, 4
• Do not assume over-the-counter agents like melatonin are safe simply because they are "natural"; human pregnancy data are insufficient to recommend routine use. 4
• Do not continue pharmacotherapy throughout pregnancy without attempting periodic tapers, especially in the second trimester when sleep often improves. 3
• Do not use adult dosing of zolpidem (10 mg) in pregnant women; pregnancy-related pharmacokinetic changes and increased sensitivity necessitate the 5 mg dose. 2, 3
• Do not fail to screen for and treat primary sleep disorders (sleep apnea, restless legs syndrome) that may be the true cause of insomnia and require specific non-pharmacologic interventions. 3